Christian Karsten Hansen (born 18 August 1966) is a Danish biotechnology entrepreneur, investor and inventor, with work in new drugs, molecular biology and biochemistry.
Personal background
Originally from Copenhagen (Denmark), he spent his childhood in Antwerp, Belgium and Caracas, Venezuela before completing high school at Sorø Academy in 1984. Following graduation as MSc chemical engineering from the Technical University of Denmark in 1989,[1] PhD work in molecular biology and biochemistry was conducted at the Pasteur Institute,[2][3][4] France and the University of Salamanca,[5] Spain. He also completed an MBA from the Edinburgh Business School, Scotland.[6]
Professional background
Hansen held positions as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management.[6] He co-founded one of the early Danish biotechnology companies, Profound Pharma,[7][8] in 1999, with Jan Møller Mikkelsen,[9] and remained co-CEO thereof until its acquisition by Maxygen in 2000.[10] In 2001, he co-founded the investment firm Nordic Biotech Advisors,[1]
Patents
Hansen has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals. He is named as inventor of issued European patents 510091,[26] 1250154,[27] 1425304,[28] 1534305,[29] 1622629,[30] 1622630,[31] 1732575,[32]
References
- Festglad venturekapitalist – Diverse Berlingske Business, Business.dk, 10 November 2005, retrieved 10 November 2011^
- C K Hansen, B Diderichsen, P L Jørgensen. celA from Bacillus lautus PL236 encodes a novel cellulose-binding endo-beta-1,4-glucanase Journal of Bacteriology, June 1992^
- Jørgensen Per L., Hansen Christian K., Poulsen Gitte B., Diderichsen Børge. Gene : In vivo genetic engineering: homologous recombination as a tool for plasmid construction Gene, 1990^